News
LCTX
1.460
-6.41%
-0.100
Lineage Cell Therapeutics Price Target Announced at $9.00/Share by Canaccord Genuity
Dow Jones · 1d ago
Lineage Cell Therapeutics Initiated at Buy by Canaccord Genuity
Dow Jones · 1d ago
Lineage Cell Therapeutics initiated with a Buy at Canaccord
TipRanks · 1d ago
Weekly Report: what happened at LCTX last week (0420-0424)?
Weekly Report · 2d ago
Weekly Report: what happened at LCTX last week (0413-0417)?
Weekly Report · 04/20 09:45
Lineage Cell Therapeutics announces formation of Scientific Advisory Board
TipRanks · 04/13 12:26
Weekly Report: what happened at LCTX last week (0406-0410)?
Weekly Report · 04/13 09:47
Lineage Cell Therapeutics management to meet with Craig-Hallum
TipRanks · 04/08 20:56
Service Properties Trust, ConocoPhillips And Other Big Stocks Moving Lower In Monday's Pre-Market Session
Benzinga · 04/06 12:03
Weekly Report: what happened at LCTX last week (0330-0403)?
Weekly Report · 04/06 09:47
Weekly Report: what happened at LCTX last week (0323-0327)?
Weekly Report · 03/30 09:47
Lineage Cell Therapeutics Is Maintained at Buy by B. Riley Securities
Dow Jones · 03/25 15:23
Lineage Cell Therapeutics Price Target Raised to $4.00/Share From $3.00 by B. Riley Securities
Dow Jones · 03/25 15:23
Wall Street Analysts Are Bullish on Top Healthcare Picks
TipRanks · 03/25 12:20
Lineage Cell Therapeutics price target raised to $4 from $3 at B. Riley
TipRanks · 03/25 12:16
Lineage Cell Therapeutics Price Target Maintained With a $9.00/Share by HC Wainwright & Co.
Dow Jones · 03/24 15:29
HC Wainwright & Co. Reiterates Buy on Lineage Cell Therapeutics, Maintains $9 Price Target
Benzinga · 03/24 15:19
Lineage Cell launches cell therapy program in corneal endothelial disease
TipRanks · 03/24 12:16
Lineage Cell Therapeutics Expands Cell Transplant Pipeline With COR1
Benzinga · 03/24 12:07
Weekly Report: what happened at LCTX last week (0316-0320)?
Weekly Report · 03/23 09:45
More
Webull provides a variety of real-time LCTX stock news. You can receive the latest news about Lineage Cell The through multiple platforms. This information may help you make smarter investment decisions.
About LCTX
Lineage Cell Therapeutics, Inc. is a clinical-stage biotechnology company developing cell replacement therapies to treat serious medical conditions. The Company programs are based on a cell-based technology platform, AlloSCOPE, which develops formulation, manufacturing, and delivery capabilities, and serves as the source of its pluripotent cell-based product candidates. Its pipeline includes OpRegen, an allogeneic retinal pigment epithelial (RPE) cell replacement therapy for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (dry-AMD); OPC1, an allogeneic oligodendrocyte progenitor cell therapy for the treatment of spinal cord injuries (SCI); ReSonance (ANP1), an allogeneic auditory neuron progenitor cell transplant therapy for the treatment of auditory neuropathy; ILT1, an allogeneic cell transplant research initiative for the treatment of Type 1 Diabetes (T1D).